These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The role of immunity in Huntington's disease. Soulet D; Cicchetti F Mol Psychiatry; 2011 Sep; 16(9):889-902. PubMed ID: 21519341 [TBL] [Abstract][Full Text] [Related]
27. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Guidetti P; Reddy PH; Tagle DA; Schwarcz R Neurosci Lett; 2000 Apr; 283(3):233-5. PubMed ID: 10754231 [TBL] [Abstract][Full Text] [Related]
28. [Huntington disease. A review]. Bonilla E Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047 [TBL] [Abstract][Full Text] [Related]
29. Drug targeting of dysregulated transcription in Huntington's disease. Kazantsev AG; Hersch SM Prog Neurobiol; 2007 Nov; 83(4):249-59. PubMed ID: 17379386 [TBL] [Abstract][Full Text] [Related]
30. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. Leegwater-Kim J; Cha JH NeuroRx; 2004 Jan; 1(1):128-38. PubMed ID: 15717013 [TBL] [Abstract][Full Text] [Related]
32. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Aharony I; Ehrnhoefer DE; Shruster A; Qiu X; Franciosi S; Hayden MR; Offen D Hum Mol Genet; 2015 May; 24(9):2604-14. PubMed ID: 25616965 [TBL] [Abstract][Full Text] [Related]
33. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740 [TBL] [Abstract][Full Text] [Related]
34. Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD. Andrich J; Saft C; Arz A; Schneider B; Agelink MW; Kraus PH; Kuhn W; Müller T Mov Disord; 2004 Feb; 19(2):226-8. PubMed ID: 14978683 [TBL] [Abstract][Full Text] [Related]
35. Small molecule drug discovery for Huntington's Disease. Fecke W; Gianfriddo M; Gaviraghi G; Terstappen GC; Heitz F Drug Discov Today; 2009 May; 14(9-10):453-64. PubMed ID: 19429504 [TBL] [Abstract][Full Text] [Related]
36. [Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features]. Bantubungi K; Blum D Rev Med Brux; 2007; 28(5):413-21. PubMed ID: 18069515 [TBL] [Abstract][Full Text] [Related]
38. Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin. Ruan Q; Quintanilla RA; Johnson GV J Neurochem; 2007 Jul; 102(1):25-36. PubMed ID: 17403029 [TBL] [Abstract][Full Text] [Related]
39. [From gene to disease; HD gene and Huntington disease]. Maat-Kievit JA; Losekoot M; Roos RA Ned Tijdschr Geneeskd; 2001 Nov; 145(44):2120-3. PubMed ID: 11723754 [TBL] [Abstract][Full Text] [Related]
40. Stem cell therapy and cellular engineering for treatment of neuronal dysfunction in Huntington's disease. Choi KA; Hwang I; Park HS; Oh SI; Kang S; Hong S Biotechnol J; 2014 Jul; 9(7):882-94. PubMed ID: 24827816 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]